Eli Lilly News | finanzen.ch

Kurse + Charts + Realtime		News + Analysen	Fundamental	Unternehmen	zugeh. Wertpapiere	Aktion
Kurs + Chart	Chart (gross)	News + Adhoc	Bilanz/GuV	Termine	Strukturierte Produkte	Portfolio
Times + Sales	Chartvergleich	Analysen	Schätzungen	Profil		Watchlist
Börsenplätze	Realtime Push	Kursziele	Dividende/GV
Orderbuch			Analysen
Historisch

Kurse + Charts + Realtime

News + Analysen

Fundamental

Unternehmen

zugeh. Wertpapiere

Strukturierte Produkte

Aktion

Portfolio

Watchlist

14.12.21	Mirikizumab Demonstrates Superiority over Placebo in Phase 3 Maintenance Study in Ulcerative Colitis, Supporting Regulatory Submissions in 2022 (PR Newswire)
13.12.21	Lilly Announces 15 Percent Dividend Increase, First-Quarter 2022 Dividend (PR Newswire)
13.12.21	Why Foghorn Therapeutics Is Rising In Pre-market? (RTTNews)
13.12.21	Lilly and Foghorn Announce Strategic Collaboration for Novel Oncology Targets Using Foghorn's Proprietary Gene Traffic Control® Platform (PR Newswire)
13.12.21	Form SC 13G 59478 (RSS)
12.12.21	Loxo Oncology at Lilly Announces Updated Data from the Phase 1/2 BRUIN Clinical Trial for Pirtobrutinib at the American Society of Hematology Annual Meeting (PR Newswire)
10.12.21	Lilly, Regor Collaborates To Discover & Develop Novel Therapies For Metabolic Disorders (RTTNews)
10.12.21	Lilly and Regor Therapeutics Group Enter into Strategic Collaboration to Discover and Develop Novel Therapies for Metabolic Disorders (PR Newswire)
09.12.21	New Lilly Study Reveals Underappreciation of Bowel Urgency as a Symptom of Ulcerative Colitis and Highlights Communication Gap Between Healthcare Providers and Patients (PR Newswire)
06.12.21	FDA Expands Authorization For Lilly's COVID-19 Antibody Therapy To Include Young Children & Infants (RTTNews)
03.12.21	Lilly's bamlanivimab with etesevimab authorized as the first and only neutralizing antibody therapy for emergency use in COVID-19 patients under the age of 12 (PR Newswire)
01.12.21	Lilly to Announce Initial 2022 Financial Guidance; Provide R&D Overview at Investment Community Meeting (PR Newswire)
29.11.21	Tetra Announces Positive Initial Data From Phase 2 Trials Of QIXLEEF For Cancer Pain (RTTNews)
18.11.21	Emgality® Versus Nurtec® ODT Head-to-Head Migraine Preventive Treatment Study Now Enrolling Patients (PR Newswire)
17.11.21	Lilly to Participate in Fourth Annual Evercore ISI HealthCONx Conference (PR Newswire)
11.11.21	US FDA accepts supplemental New Drug Application and grants Priority Review for Jardiance® for adults with heart failure independent of left ventricular ejection fraction (PR Newswire)
11.11.21	Lilly announces winners of inaugural Leonard Award, a global program celebrating 100 years of innovation in diabetes care (PR Newswire)
09.11.21	Lilly to Participate in Wolfe Research Virtual Healthcare Conference (PR Newswire)
09.11.21	OLUMIANT® Long-Term Safety Profile Established Up to 9.3 Years in Integrated Analysis of More Than 3,700 Patients with Rheumatoid Arthritis (PR Newswire)
05.11.21	Jardiance® shows consistent cardio-renal benefits in adults with heart failure with left ventricular ejection fraction over 40% regardless of chronic kidney disease status (PR Newswire)
04.11.21	Loxo Oncology at Lilly Announces Details of Presentations at the 2021 American Society of Hematology (ASH) Annual Meeting (PR Newswire)
02.11.21	Lilly To Supply 614K Additional Doses Of Bamlanivimab And Etesevimab To The US (RTTNews)
02.11.21	Lilly to supply 614,000 additional doses of bamlanivimab and etesevimab to the U.S. Government for the treatment or post-exposure prevention of COVID-19 (PR Newswire)
01.11.21	Lilly to Participate in Bernstein's Second Annual Operational Decisions Conference (PR Newswire)
28.10.21	Additional Verzenio® (abemaciclib) Phase 3 monarchE Trial Data Published in the Annals of Oncology (PR Newswire)
26.10.21	Lilly Lifts FY21 Adj. EPS, Revenue View Above Market - Quick Facts (RTTNews)
26.10.21	Eli Lilly And Co. Profit Drops In Q3 (RTTNews)
26.10.21	Lilly Reports Robust Third-Quarter 2021 Financial Results as Pipeline Success Strengthens Future Growth Potential (PR Newswire)
19.10.21	Lilly : Phase 3 Tirzepatide Results Show Superior A1C And Body Weight Reductions In Type 2 Diabetes (RTTNews)
19.10.21	Tirzepatide results published in The Lancet show superior A1C and body weight reductions compared to insulin glargine in adults with type 2 diabetes with increased cardiovascular risk (PR Newswire)
18.10.21	Lilly Declares Fourth-Quarter 2021 Dividend (PR Newswire)
14.10.21	Lilly Announces Updated Verzenio® (abemaciclib) Phase 3 monarchE Trial Data Presented at ESMO Virtual Plenary and Simultaneously Published in the Annals of Oncology (PR Newswire)
13.10.21	Eli Lilly: FDA Approves Verzenio In Adjuvant Treatment Of HR+ HER2- Early Breast Cancer (RTTNews)
13.10.21	FDA Approves Verzenio® (abemaciclib) as the First and Only CDK4/6 Inhibitor for Certain People with HR+ HER2- High Risk Early Breast Cancer (PR Newswire)
12.10.21	Lilly Confirms Date and Conference Call for Third-Quarter 2021 Financial Results Announcement (PR Newswire)
12.10.21	COVAX Exercises Option To Purchase 176.5 Mln Addl Doses Of Moderna COVID-19 Vaccine In H1 2022 (RTTNews)
07.10.21	Loxo Oncology at Lilly Announces Details of Presentations at 2021 AACR-NCI-EORTC Virtual International Conference on Molecular Targets and Cancer Therapeutics (PR Newswire)
07.10.21	Sonoco To Implement Price Increase For Uncoated Recycled Paperboard (RTTNews)
04.10.21	Ready for the Challenge? Boehringer Ingelheim and Eli Lilly and Company Launch First Ever Online Game on Cardio-Renal-Metabolic Conditions for Healthcare Professionals (PR Newswire)
01.10.21	At Week 104, 75% of Patients with Ulcerative Colitis Taking Mirikizumab Maintained Symptomatic Remission in Phase 2 Study (PR Newswire)
30.09.21	Lilly, Incyte Present Detailed Results From OLUMIANT BRAVE-AA1, BRAVE-AA2 Trials In Alopecia Areata (RTTNews)
30.09.21	OLUMIANT® Significantly Improved Hair Regrowth to At Least 80% Scalp Coverage as Early as 24 Weeks Across First Completed Phase 3 Studies for Alopecia Areata (PR Newswire)
30.09.21	Lilly Reports Positive Results From Two SURPASS-3 Sub-studies Of Tirzepatide In Type 2 Diabetes (RTTNews)
30.09.21	Lilly's tirzepatide led to greater improvements in liver fat content compared to insulin degludec in adults with type 2 diabetes in SURPASS-3 MRI sub-study (PR Newswire)
30.09.21	Lilly's tirzepatide led to greater time in range compared to insulin degludec in adults with type 2 diabetes in SURPASS-3 CGM sub-study (PR Newswire)
29.09.21	Lilly and Susan G. Komen® Partner to Address Disparities in Breast Cancer Outcomes Experienced By Black Women (PR Newswire)
29.09.21	FDA Expands Lilly's Erbitux Label With Braftovi For Treatment Of Metastatic Colorectal Cancer (RTTNews)
28.09.21	FDA Expands Lilly's ERBITUX® (cetuximab) Label with Combination of BRAFTOVI® (encorafenib) for the Treatment of BRAF V600E Mutation-Positive Metastatic Colorectal Cancer (CRC) after Prior Therapy (PR Newswire)
28.09.21	Lilly Cuts List Price Of Insulin Lispro Injection In U.S. Again, Effective Jan. 1 (RTTNews)
28.09.21	Lilly again reduces list price of Insulin Lispro Injection as latest change to affordability options (PR Newswire)

Newssuche

SMI
SPI
SLI
SMIM
DAX
ESTOXX
Dow Jones
S&P 500
NASDAQ 100
Nikkei 225

Part Grp Hldg	1’263.50	2.89 %	K V
Sonova Hldg	312.10	2.66 %	K V
Novartis	93.68	2.32 %	K V
Geberit	526.80	1.97 %	K V
Roche Hldg G	254.30	1.27 %	K V
Kuehne+Nagel Int	209.50	0.72 %	K V
UBS Group	28.30	0.57 %	K V
Givaudan	3’933.00	0.36 %	K V
Nestle	76.00	0.05 %	K V
Lonza Grp	521.40	-0.04 %	K V

mehr

22.11.24		Dow Jones aktuell: Dow Jones zum Ende des Freitagshandels in der Gewinnzone
22.11.24		SIX-Handel: SLI zeigt sich zum Ende des Freitagshandels fester
22.11.24		Pluszeichen in Zürich: SMI zum Ende des Freitagshandels mit grünem Vorzeichen
22.11.24		Gute Stimmung in Europa: Anleger lassen STOXX 50 letztendlich steigen
22.11.24		Deutsche Bank AG: Novartis-Aktie erhält Hold
22.11.24		Freitagshandel in New York: Dow Jones zum Start des Freitagshandels fester
22.11.24		Optimismus in Europa: So entwickelt sich der Euro STOXX 50 am Freitagnachmittag
22.11.24		Pluszeichen in Europa: STOXX 50 notiert im Plus